|
Forecast
Period
|
2024-2028
|
|
Market
Size (2022)
|
USD
159.21 million
|
|
CAGR
(2023-2028)
|
9.12%
|
|
Fastest
Growing Segment
|
Targeted
Sequencing & Resequencing Centrifuges
|
|
Largest
Market
|
Mid-West
|
Market Overview
United States Clinical Oncology Next Generation
Sequencing Market has valued at USD 159.21 million in 2022 and is anticipated
to project robust growth in the forecast period with a CAGR of 9.12% through
2028. The United States Clinical Oncology Next Generation Sequencing (NGS)
market is a dynamic and rapidly evolving sector within the broader healthcare
and life sciences industry. NGS technology, also known as high-throughput
sequencing, has revolutionized the field of clinical oncology by enabling the
comprehensive analysis of a patient's genetic makeup and the genetic
alterations present in their cancer cells. This market overview will provide a
brief snapshot of the key trends, drivers, and challenges shaping the landscape
of clinical oncology NGS in the United States.
NGS has emerged as a powerful tool for precision
medicine, allowing oncologists to tailor cancer treatments to an individual's
unique genetic profile. This approach has the potential to improve patient
outcomes, minimize adverse effects, and enhance the overall quality of cancer
care. The United States is a global leader in clinical oncology NGS, with
numerous academic institutions, research centers, and biotechnology companies
actively engaged in cutting-edge research and development.
Key drivers of this market include the growing
incidence of cancer, rising awareness about the potential benefits of precision
medicine, and the continuous advancement of NGS technologies. Additionally, the
decreasing cost of sequencing and the expansion of reimbursement policies for
NGS-based tests are making these technologies more accessible to a wider
patient population.
However, there are challenges to address in the
clinical oncology NGS market, including regulatory and data privacy concerns,
as well as the need for robust bioinformatics and data analysis capabilities.
Ensuring the integration of NGS into routine clinical practice and establishing
standardized protocols are ongoing priorities.
Key Market Drivers
Rising Incidence of Cancer
The United States Clinical Oncology Next Generation
Sequencing (NGS) market is experiencing a substantial boost driven by the
rising incidence of cancer. Cancer remains a formidable challenge in the United
States, with a growing number of individuals being diagnosed with various forms
of the disease each year. This escalating incidence has created an urgent need
for more advanced and precise diagnostic and treatment approaches, which is
where NGS technology comes into play.
One of the primary factors contributing to the
increased incidence of cancer is an aging population. As the baby boomer
generation continues to grow older, the risk of cancer rises, as the disease is
more commonly associated with aging. This demographic shift has put a higher
burden on the healthcare system to diagnose and treat cancer effectively.
Furthermore, lifestyle factors, such as unhealthy
diets, lack of physical activity, and exposure to environmental carcinogens,
have also contributed to the rising cancer rates. These modifiable risk factors
have led to increased prevalence of various cancer types, necessitating more
effective methods for early detection and tailored treatment.
NGS technology is instrumental in addressing these
challenges. It allows for a comprehensive analysis of a patient's genetic and
molecular makeup, enabling oncologists to identify specific genetic mutations
and alterations driving the development of cancer. This information is
invaluable for making informed decisions about treatment approaches. NGS
facilitates the development of personalized treatment plans, which can result
in higher treatment success rates and fewer adverse effects, thereby improving
the quality of life for cancer patients.
In addition, NGS-based tests are at the forefront
of early cancer detection and screening efforts. As the incidence of cancer
continues to rise, early detection becomes increasingly critical, as it
significantly improves the chances of successful treatment. NGS technology
enables the identification of cancer-related biomarkers and circulating tumor
DNA, allowing for the early diagnosis and monitoring of cancer, even before
symptoms manifest.
Advancements in NGS Technologies
Advancements in Next Generation Sequencing (NGS)
technologies are playing a pivotal role in boosting the United States Clinical
Oncology NGS market. These innovations are revolutionizing the landscape of
cancer diagnosis, treatment, and research, offering remarkable benefits in
terms of precision, speed, and accessibility.
the rapid progress in NGS technology has resulted
in platforms that offer faster and more cost-effective sequencing. This has
made NGS more accessible to a broader range of healthcare institutions and
research facilities, reducing the barriers to entry and allowing smaller and
non-specialized laboratories to embrace this technology. As a result, NGS is
becoming increasingly integrated into routine clinical oncology practice.
Furthermore, advancements in NGS technologies have
significantly improved the accuracy and sensitivity of sequencing, making it
possible to detect genetic mutations and variations associated with cancer with
greater precision. These technologies now enable comprehensive profiling of
tumor genomes, providing oncologists with a wealth of information to guide
personalized treatment strategies. The ability to identify specific genetic
alterations driving cancer empowers oncologists to choose targeted therapies that
are more likely to be effective, resulting in better patient outcomes.
NGS technologies have also expanded to encompass
various applications, such as RNA sequencing for gene expression analysis and
epigenetic modifications. This broad range of applications enables
comprehensive insights into the underlying molecular mechanisms of cancer,
allowing for a deeper understanding of the disease and its treatment. The
ability to explore not only DNA but also RNA and epigenetic changes broadens
the scope of what can be analyzed, providing a more holistic view of cancer
biology.
Moreover, the continuous development of NGS
platforms is driving the growth of the Clinical Oncology NGS market by enabling
the identification of unique genetic alterations associated with cancer
subtypes and rare genetic mutations. This is particularly crucial in the era of
personalized medicine, where tailoring treatment to the specific
characteristics of a patient's cancer is the cornerstone of effective care.
Rise in Personalized Medicine
The rise of personalized medicine is a significant
driving force behind the burgeoning United States Clinical Oncology Next
Generation Sequencing (NGS) market. Personalized medicine, also known as
precision medicine, represents a groundbreaking approach to patient care that
takes into account individual genetic variations, making it particularly
impactful in the field of clinical oncology.
Personalized medicine leverages NGS technology to
decode a patient's unique genetic makeup, allowing oncologists to tailor
treatment strategies with unparalleled precision. The primary goal is to
provide patients with therapies that are specifically designed to target the
genetic mutations and alterations driving their particular form of cancer. This
approach not only enhances the effectiveness of treatment but also minimizes
potential side effects, ultimately improving the quality of life for cancer patients.
The NGS-based genomic profiling made possible by
personalized medicine empowers healthcare providers to make data-driven
decisions. This includes the identification of actionable genetic mutations and
alterations, as well as the ability to predict treatment responses, which is
especially crucial in the rapidly evolving landscape of cancer therapies. With
the increasing availability of targeted therapies and immunotherapies, the
ability to match the right treatment to the right patient is becoming paramount.
Moreover, personalized medicine in clinical
oncology is not limited to treatment decisions. It also extends to risk
assessment and early detection. NGS-based tests can identify genetic
predispositions to cancer, allowing for proactive measures such as increased
surveillance and preventive interventions for individuals at higher risk due to
inherited mutations. This approach is particularly valuable for individuals
with a family history of cancer.
The demand for NGS technology in clinical oncology
has surged in response to the rise of personalized medicine. Both healthcare
providers and patients are increasingly recognizing the value of integrating
NGS into the diagnostic and treatment process. The potential for more
effective, personalized care is a driving force behind this market growth.
Download Free Sample Report
Key Market Challenges
Data Privacy and Security
The United States Clinical Oncology Next Generation
Sequencing (NGS) market has made remarkable strides in advancing cancer
diagnosis, treatment, and research. However, it faces a significant challenge
that cannot be ignored - data privacy and security concerns. The sensitive and
personal nature of patient genetic and clinical data obtained through NGS has
raised critical issues regarding confidentiality and protection.
Patients undergoing NGS testing have their genetic
and clinical data stored and analyzed. This information is among the most
private and intimate a person can provide. Ensuring that this data remains
confidential and secure is paramount. Any breach could have severe
consequences, including identity theft, discrimination, or misuse of this
information.
Healthcare organizations, laboratories, and
research institutions must adhere to strict data privacy regulations, such as
the Health Insurance Portability and Accountability Act (HIPAA). Ensuring
compliance is not only a legal obligation but also a significant operational
challenge, requiring stringent measures and investments in technology and staff
training.
The vast amount of data generated by NGS requires
secure storage and retention policies. Ensuring that this data is protected
from theft or unauthorized access is crucial and maintaining it over extended
periods can be costly and complex.
Like other sectors, the Clinical Oncology NGS
market is vulnerable to cyberattacks. Hackers and cybercriminals may target
organizations to steal patient data, leading to data breaches with severe
consequences. Protecting NGS data from these threats requires robust
cybersecurity measures and continuous monitoring.
Patients must provide informed consent before their
genetic data is sequenced and analyzed. Ensuring that patients fully understand
the implications of NGS and the use of their data for research and clinical
care is an ongoing challenge.
Cost and Accessibility
One of the primary challenges in the Clinical
Oncology NGS market is the high cost associated with NGS technology. While NGS
has become more affordable over the years, comprehensive sequencing remains
relatively expensive. The cost includes not only the actual sequencing but also
data analysis, interpretation, and the equipment required for this highly
specialized field.
The expenses associated with NGS can be a
significant barrier for both healthcare institutions and patients. The initial
investment in NGS equipment, the cost of consumables, and the need for skilled
personnel to operate the technology can strain the budgets of hospitals and
research institutions. This can limit the capacity of these facilities to offer
NGS-based tests and services to their patients.
Accessibility to NGS services in clinical oncology
is another significant challenge. Not all healthcare facilities, particularly
in underserved or rural areas, have the resources and expertise to offer
NGS-based tests. This creates disparities in access to cutting-edge cancer
care, as patients in these areas may not benefit from the latest advancements
in precision medicine.
Furthermore, even in urban areas with advanced
healthcare systems, not all patients have equal access to NGS services.
Socioeconomic factors, insurance coverage, and geographic location can limit
access to NGS-based testing and treatments. This disparity in access can result
in unequal healthcare outcomes, as patients who could benefit from NGS may miss
out on the advantages it offers.
Key Market Trends
Growth in Genomic Medicine
The growth of genomic medicine is playing a pivotal
role in boosting the United States Clinical Oncology Next Generation Sequencing
(NGS) market. Genomic medicine, which involves the application of genetic
information in healthcare, is increasingly recognized as a game-changer in the
field of clinical oncology. The integration of genomics into clinical practice
has shifted the paradigm of cancer care towards more personalized and effective
approaches.
Genomic medicine harnesses the power of NGS
technology to decode the genetic makeup of an individual's tumor. This allows
oncologists to understand the genetic alterations that drive cancer and
identify potential therapeutic targets with unparalleled precision. By gaining
comprehensive insights into the genetic and molecular underpinnings of a
patient's cancer, healthcare providers can tailor treatment plans to address
the specific genetic abnormalities present, thereby improving the chances of
treatment success and minimizing adverse effects.
Moreover, the growth of genomic medicine has led to
a greater understanding of the genetic predisposition to cancer. NGS-based
tests can identify inherited genetic mutations that increase the risk of
developing cancer. This knowledge allows for more proactive measures such as
increased surveillance, risk-reduction strategies, and preventive
interventions, which are especially valuable for individuals with a family
history of cancer.
The demand for NGS-based tests in the clinical
oncology space has surged in response to this growth in genomic medicine.
Oncologists and healthcare institutions increasingly recognize the value of
integrating NGS into their diagnostic and treatment workflows. As a result, the
Clinical Oncology NGS market is thriving, driven by the need for more precise
and personalized cancer care.
Data Analysis and Interpretation Tools
Advanced data analysis tools can identify
clinically actionable genetic mutations, helping oncologists select the most
appropriate treatment options for individual patients. They enable healthcare
providers to make data-driven decisions that can lead to more effective and
personalized cancer therapies.
NGS data analysis can be a time-consuming process,
especially in the context of clinical care where timely decisions are crucial.
Robust data analysis tools streamline the process, reducing the time required
to turn raw sequencing data into clinically relevant information. This
efficiency is particularly important in rapidly progressing oncology cases.
Human interpretation of NGS data is prone to errors
and subjectivity. Advanced data analysis tools provide more consistency and
accuracy, minimizing the risk of misinterpretation and ensuring that results
are reliable for clinical decision-making.
NGS generates a massive amount of data that can be
challenging to manage effectively. Data analysis tools include features for
data storage, organization, and retrieval, simplifying the handling of large
datasets and ensuring that pertinent information is readily accessible when
needed.
Different clinical scenarios may require unique
data analysis approaches. The ability to customize data analysis tools allows
healthcare providers to adapt to specific patient needs, disease types, and
research objectives. This flexibility is essential in the rapidly evolving
field of clinical oncology.
Data analysis tools that seamlessly integrate with
existing clinical workflows and electronic health record (EHR) systems
facilitate the efficient incorporation of NGS data into patient care. This
integration ensures that NGS results are readily accessible to healthcare
teams, contributing to a holistic approach to patient management.
In the era of collaborative research and data
sharing, data analysis tools that adhere to standardized formats and can be
used across multiple institutions are invaluable. These tools foster
collaboration, accelerate knowledge exchange, and drive innovation in clinical
oncology.
Segmental Insights
Technology Insights
Based on the Technology , Whole Exome Sequencing emerged
as the dominant segment in the United States market for United States Clinical
Oncology Next Generation Sequencing Market in 2022. Whole Exome Sequencing specifically targets the
protein-coding regions of the genome, known as exomes. These regions contain a
majority of the known disease-associated variants. By concentrating on these
areas, WES can efficiently identify genetic mutations that are more likely to
be causative in oncology, making it a practical choice for clinical
applications. Whole Genome Sequencing (WGS) is comprehensive but often
expensive, given the vast amount of data generated. WES provides a more
cost-effective alternative by sequencing only the exome, which significantly
reduces the data size while still capturing crucial genetic information. This
cost-effectiveness is essential for widespread clinical adoption.
In clinical oncology, time is often of the essence,
and WES offers a more focused and faster analysis than WGS. It helps identify
actionable genetic mutations with clinical relevance, aiding in treatment
decisions and therapeutic approaches tailored to the patient's specific
condition..
Workflow Insights
Based on the Workflow, the NGS
Sequencing segment emerged as the dominant player in the United States market
for United States Clinical Oncology Next Generation Sequencing Market in 2022. NGS Sequencing directly addresses the core
objective of clinical oncology NGS, which is the generation of genetic and
genomic data from patient samples. It is the central step in the process, where
the actual sequencing of DNA or RNA occurs, providing the raw genetic
information necessary for the diagnosis, treatment, and research in oncology.
NGS Sequencing generates vast amounts of data that
encompass the entire genome or specific regions of interest. This comprehensive
approach is critical in identifying genetic mutations, variants, and
abnormalities associated with cancer. It enables the profiling of the entire
genome or specific genomic regions, allowing for a deep exploration of
potential cancer drivers. NGS Sequencing is the foundation for clinical
diagnosis and treatment decisions in oncology. It reveals genetic alterations,
such as mutations and translocations, that inform precision medicine
approaches. By identifying these specific genetic changes, oncologists can
tailor treatments to the patient's unique genetic profile, optimizing
therapeutic outcomes.
Download Free Sample Report
Regional Insights
Mid-West emerged as the dominant player in the United
States Clinical Oncology Next Generation Sequencing Market in 2022, holding the
largest market share Access
to Funding: The East region is often a hub for medical research and
biotechnology innovation, attracting substantial funding from government
agencies, private investors, and philanthropic organizations. This financial
support bolsters the development and adoption of NGS technologies in clinical
oncology. Leading hospitals and cancer treatment centers in the East region are
renowned for their clinical excellence and patient care. The demand for NGS in
clinical oncology is driven by the commitment to providing the best possible
care to patients, and the East region's healthcare institutions are known for
their clinical expertise and innovation.
Recent Developments
- In June 2023, Invivoscribe, a U.S.-based company
specializing in oncology testing products and services, joined forces with
Complete Genomics, a provider of DNA sequencing solutions, to co-create
biomarker tests for oncology and cancer research. Within this collaborative
effort, Complete Genomics is contributing its Next-Generation Sequencing (NGS)
platforms.
- In June 2023, U.S.-based company PreCheck Health
Services Inc. unveiled an extensive cancer panel, leveraging Next Generation
Sequencing technology for comprehensive oncological analysis.
Key Market Players
- Illumina, Inc.
- Thermo
Fisher Scientific Inc.
- F.
Hoffmann-La Roche Ltd.
- Agilent
Technologies
- Myriad
Genetics
- Beijing
Genomics Institute (BGI)
- Perkin
Elmer
- Foundation
Medicine
- Pacific
Bioscience
- Oxford
Nanopore Technologies Ltd.
|
By Technology
|
By Workflow
|
By Application
|
By End Use
|
By Region
|
- Whole Exome Sequencing
- Targeted Sequencing & Resequencing
Centrifuges
|
- NGS Pre-Sequencing
- NGS Sequencing
- NGS Data Analysis
|
- Screening
- Companion Diagnostics
- Other Diagnostics
|
- Hospitals
- Clinics
- Laboratories
|
- North-East
- Mid-west
- West
- South Whole Genome Sequencing
|
Report Scope:
In this report, the United States Clinical Oncology
Next Generation Sequencing Market has
been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- United States Clinical Oncology Next
Generation Sequencing Market, By
Technology:
o Whole Exome Sequencing
o Targeted Sequencing & Resequencing Centrifuges
- United States Clinical Oncology Next
Generation Sequencing Market, By
Workflow:
o NGS Pre-Sequencing
o NGS Sequencing
o NGS Data Analysis
- United States Clinical Oncology Next
Generation Sequencing Market, By
Application:
o Screening
o Companion Diagnostics
o Other Diagnostics
- United States Clinical Oncology Next
Generation Sequencing Market, By
End Use:
o Hospitals
o Clinics
o Laboratories
- United States Clinical Oncology Next
Generation Sequencing Market, By Region:
o North-East
o Mid-west
o West
o South
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the United
States Clinical Oncology Next Generation Sequencing Market.
Available Customizations:
United States Clinical Oncology Next Generation
Sequencing Market report with the given market data, Tech Sci Research offers
customizations according to a company's specific needs. The following
customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
United States
Clinical Oncology Next Generation Sequencing Market is an upcoming report to be released soon.
If you wish an early delivery of this report or want to confirm the date of
release, please contact us at [email protected]